Starte jetzt beim Kostensieger der Stiftung Warentest (12/2025)

Bei unserem Broker finanzen.net ZERO handelst du alle deine Aktien ohne Ordergebühren (zzgl. Spreads). Wechsle jetzt und spare bei jedem Trade!

Nicht mehr anzeigen

Teva Pharmaceutical Industries Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

28,90 EUR -0,20 EUR -0,69 %

20.02.2026

BMN

34,37 USD +0,16 USD +0,47 %

nachbörslich20.02.2026

BTT

Teva Pharmaceutical Industries jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

KGV25,54Div. Rendite0,00%

WKN883035

ISINUS8816242098

SymbolTEVA

Teva Pharmaceutical Industries Aktien News

Sortieren:Datum Meistgelesen

06.12.24GlobeNewswireTeva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

04.12.24GlobeNewswireTeva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE

04.12.24GlobeNewswireTeva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

26.11.24GlobeNewswireTeva to Present at the 7th Annual Evercore ISI HealthCONx Conference

08.11.24GlobeNewswireTeva to Present at the Jefferies London Healthcare Conference

01.11.24GlobeNewswireTeva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

01.11.24GlobeNewswireTeva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanza

31.10.24GlobeNewswireTeva Statement on European Commission Decision; Company to Appeal

22.10.24GlobeNewswireAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us

08.10.24GlobeNewswireTeva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

03.10.24GlobeNewswireTeva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

01.10.24GlobeNewswireTeva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

30.09.24GlobeNewswireTeva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

23.09.24GlobeNewswireTeva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

21.09.24GlobeNewswireTeva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed

21.09.24GlobeNewswireNew Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

11.09.24GlobeNewswireTeva to Present at the Bank of America 2024 Global Healthcare Conference

26.08.24GlobeNewswireTeva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Teva Pharmaceutical Industries News

Teva Pharmaceutical Industries News: auf dieser Seite finden Sie alle Teva Pharmaceutical Industries News und Nachrichten zur Teva Pharmaceutical Industries Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Teva Pharmaceutical Industries News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Teva Pharmaceutical Industries News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.